Joerg Herrmann MDProfessor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
Dr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently he is an Associate Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.
Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals. He is also a contributor to Braunwald’s Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and is the editor of the textbook Clinical Cardio-Oncology.
His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.
Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib.
Recent Contributions to PracticeUpdate:
- ACC.15: Dr. Joerg Herrmann on the ERRICA, MATRIX, and DANAMI3-PRIMULTI Trials
- Validation of the Appropriate Use Criteria for Coronary Angiography
- ACC.15: Stents vs Bypass Surgery for Left Main Coronary Artery Disease in PRECOMBAT
- ACC.15: TAVR vs SAVR in Patients with Severe Aortic Valve Stenosis—The NOTION Trial
- ACC.15: CABG Bests Everolimus-Eluting Stents in Coronary Artery Disease
- ACC.15–Dr. Joerg Herrmann Reports In: Day 2
- ACC.15: No Clear Winner in PROMISE
- ACC.15: Interpreting the PROMISE Results
- ACC.15: PEGASUS-TIMI 54–Ticagrelor Improves Outcomes at Expense of Higher Bleeding Risk
- Temporal Trends in Revascularization Strategy and Outcomes in Left Main Coronary Artery Stenosis